Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) Rx Only

Manufacturer
Bryant Ranch Prepack
Effective date
2024-12-24
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
103
Source
full-release
Hydrated at
2026-05-31 21:37:53

Label at a glance#

ProductCiclopirox Olamine
Active ingredientCICLOPIROX OLAMINE
Label structure13 sections

Indications and uses

Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; cutaneous candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur .

Dosage and administration

Gently massage Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) into the affected and surrounding skin areas twice daily, in the morning and evening. Clinical improvement with relief of pruritus and other symptoms usually occurs within the first week of treatment. If a patient shows no clinical improvement after four weeks of treatment with Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lot...

Storage and handling

Store at 20° to 25° C (68° to 77° F) [see USP Controlled Room Temperature].

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

FOR DERMATOLOGIC USE ONLY.

NOT FOR USE IN EYES.

DESCRIPTION

DESCRIPTION SECTION

Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) is for topical use.

Each gram of Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) contains 7.70 mg of ciclopirox (as ciclopirox olamine) in a water miscible suspension base consisting of benzyl alcohol (1% as a preservative), cetyl alcohol, lactic acid, light mineral oil, myristyl alcohol, octyldodecanol, polysorbate 60, purified water, sorbitan monostearate, and stearyl alcohol.

Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) contains a synthetic, broad-spectrum, antifungal agent ciclopirox (as ciclopirox olamine).

The chemical name is 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone, 2-aminoethanol salt.

The CAS Registry Number is 41621-49-2.

Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) has a pH of 7. The chemical structure is:

Structural Formula
Structural Formula

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Ciclopirox is a broad-spectrum, antifungal agent that inhibits the growth of pathogenic dermatophytes, yeasts, and Malassezia furfur. Ciclopirox exhibits fungicidal activity in vitro against isolates of Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, Microsporum canis, and Candida albicans.

Pharmacokinetic studies in men with radiolabeled ciclopirox solution in polyethylene glycol 400, showed an average of 1.3% absorption of the dose when it was applied topically to 750 cm2 on the back followed by occlusion for 6 hours.

The biological half-life was 1.7 hours and excretion occurred via the kidney. Two days after application only 0.01% of the dose applied could be found in the urine. Fecal excretion was negligible.

Autoradiographic studies with human cadaver skin showed that ciclopirox penetrates into the hair and through the epidermis and hair follicles into the sebaceous glands and dermis, while a portion of the drug remains in the stratum corneum.

In vitro penetration studies in frozen or fresh excised human cadaver and pig skin indicated that the penetration of ciclopirox olamine topical suspension, 0.77% is equivalent to that of ciclopirox (ciclopirox olamine) cream 0.77%. Therapeutic equivalence of cream and suspension formulations was also indicated by studies of experimentally induced guinea pig and human trichophytosis.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; cutaneous candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) is contraindicated in individuals who have shown hypersensitivity to any of its components.

WARNINGS

WARNINGS SECTION

General -

SPL UNCLASSIFIED SECTION

Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) is not for ophthalmic use. Keep out of reach of children.

PRECAUTIONS

PRECAUTIONS SECTION

If a reaction suggesting sensitivity or chemical irritation should occur with the use of Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion), treatment should be discontinued and appropriate therapy instituted.

Information for Patients -

INFORMATION FOR PATIENTS SECTION

The patient should be told to:

  1. Use the medication for the full treatment time even though signs/symptoms may have improved and notify the physician if there is no improvement after four weeks.
  2. Inform the physician if the area of application shows signs of increased irritation (redness, itching, burning, blistering, swelling, oozing) indicative of possible sensitization.
  3. Avoid the use of occlusive wrappings or dressings.

Carcinogenesis, Mutagenesis, Impairment of Fertility -

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

A carcinogenicity study in female mice dosed cutaneously twice per week for 50 weeks followed by a 6-month drug-free observation period prior to necropsy revealed no evidence of tumors at the application site.

The following in vitro and in vivo genotoxicity tests have been conducted with ciclopirox olamine: studies to evaluate gene mutation in the Ames Salmonella/Mammalian Microsome Assay (negative) and Yeast Saccharomyces Cerevisiae Assay (negative) and studies to evaluate chromosome aberrations in vivo in the Mouse Dominant Lethal Assay and in the Mouse Micronucleus Assay at 500 mg/kg (negative).

The following battery of in vitro genotoxicity tests were conducted with ciclopirox: a chromosome aberration assay in V79 Chinese Hamster Cells, with and without metabolic activation (positive); a gene mutation assay in the HGPRT - test with V79 Chinese Hamster Cells (negative); and a primary DNA damage assay (i.e., unscheduled DNA Synthesis Assay in A549 Human Cells (negative)). An in vitro Cell Transformation Assay in BALB/C3T3 Cells was negative for cell transformation. In an in vivo Chinese Hamster Bone Marrow Cytogenetic Assay, ciclopirox was negative for chromosome aberrations at 5000 mg/kg.

Pregnancy Category B -

PREGNANCY SECTION

Reproduction studies have been performed in the mouse, rat, rabbit, and monkey, via various routes of administration, at doses 10 times or more the topical human dose and have revealed no significant evidence of impaired fertility or harm to the fetus due to ciclopirox. There are, however, no adequate or well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers -

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Caution should be exercised when Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) is administered to a nursing woman.

Pediatric Use -

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients below the age of 10 years have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

In the controlled clinical trial with 89 patients using ciclopirox olamine topical suspension and 89 patients using the vehicle, the incidence of adverse reactions was low. Those considered possibly related to treatment or occurring in more than one patient were pruritus, which occurred in two patients using ciclopirox olamine topical suspension and one patient using the suspension vehicle, and burning, which occurred in one patient using ciclopirox olamine topical suspension.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Gently massage Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) into the affected and surrounding skin areas twice daily, in the morning and evening. Clinical improvement with relief of pruritus and other symptoms usually occurs within the first week of treatment. If a patient shows no clinical improvement after four weeks of treatment with Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) the diagnosis should be redetermined. Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.

HOW SUPPLIED

HOW SUPPLIED SECTION

Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) is available as follow:

NDC: 72162-1406-3: 30 mL in a BOTTLE

NDC: 72162-1406-6: 60 mL in a BOTTLE

Bottle space provided to allow for vigorous shaking before each use.

Repackaged/Relabeled by:
Bryant Ranch Prepack, Inc.
Burbank, CA 91504

STORAGE AND HANDLING SECTION

Store at 20° to 25° C (68° to 77° F) [see USP Controlled Room Temperature].

SPL UNCLASSIFIED SECTION

Manufactured By Padagis

Yeruham, Israel

Distributed By

Padagis

Allegan, MI 49010 • www.padagis.com

Rev 01-22

98L00 RC J1

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Ciclopirox Olamine 0.77% Lotion, USP 30 mL

Label
Label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
309290ciclopirox 0.77 % Topical LotionPSN103
309290ciclopirox 7.7 MG/ML Topical LotionSCD103
309290ciclopirox 0.77 % (ciclopirox olamine 1 % ) Topical LotionSY103
309290ciclopirox 0.77 % Topical LotionSY103

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
CICLOPIROX Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
d24c6245-86b5-4444-bc75-c1ac73ab3016Product name120180612
c7015f08-288e-4cfa-93b5-f4959a4814aeProduct name120150324
3f974526-143f-9d19-ee0c-98eeee0cdc3fProduct name120140508
5c035cac-559a-7171-c5cb-f0bd0d0fbc86Product name120140508
9869efd7-d6dd-0665-5b67-53adbe6ef15eProduct name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
72162-1406-3Ciclopirox Olamine30 mL in 1 BOTTLESUSPENSION30103
72162-1406-3Ciclopirox Olamine1 in 1 CARTONSUSPENSION1103
72162-1406-6Ciclopirox Olamine1 in 1 CARTONSUSPENSION1103
72162-1406-6Ciclopirox Olamine60 mL in 1 BOTTLESUSPENSION60103

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
72162-1406-3ML - Milliliter72162-1406dda894df-005a-43bb-a7ba-e43e31bc5de212023-12-05
72162-1406-6ML - Milliliter72162-140651672362-9493-4104-8e5f-de36da8d880512025-02-10
45802-400-46ML - Milliliter45802-400fcd30868-d8e6-4d9f-a1e5-9f27cdcf24fa12012-07-24
45802-400-49ML - Milliliter45802-4002ff0072a-ed91-42a8-a83c-776c8ad6064a12012-07-24

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 12 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
72162-140672162-1406-3, 72162-1406-6
45802-400

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 11 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A077676-001CICLOPIROXCICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-15

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A077676-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-15c2088c7a36db…
2026-09-14 22:38:342026-08A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-1584e616aacf4f…
2026-08-18 06:07:402026-07A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-15caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-15011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-1531067a03dcf5…
2025-08-23 18:47 UTC2025-08A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-156a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-15fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-15b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-1503ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-152680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-155bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-15d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-15d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-1579d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-15301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-151e350fbaab3a…
2024-05-31 18:47 UTC2024-05A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-158072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-155c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-155d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-154b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-1574a2ff9319b5…
2022-03-09 01:35 UTC2022-03A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-15bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-15782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-1587673890dc5c…
2021-03-12 10:30 UTC2021-03A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-155aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-158869cabd3fbd…
2020-11-12 02:37 UTC2020-11A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-15c0c555d07b60…
2019-12-14 00:12 UTC2019-12A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-153f01610625f2…
2019-09-15 20:21 UTC2019-09A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-15b00525d2431f…
2019-07-19 19:46 UTC2019-07A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-15ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-156a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-151c564ffb4f44…
2023-12-20 04:57 UTC2023-12A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-15ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-15a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-159b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-15a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-153f0d92c62455…
2023-05-13 08:27 UTC2023-05A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-15053a50430f4f…
2023-01-26 05:58 UTC2023-01A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-153bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A077676-001CICLOPIROX0.77%SUSPENSION / TOPICALAB2006-12-153a93d1ddd44b…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-10-15 13:18:302026-09A077676-001AB1c2088c7a36db…
2026-09-14 22:38:342026-08A077676-001AB184e616aacf4f…
2026-08-18 06:07:402026-07A077676-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A077676-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A077676-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08A077676-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A077676-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A077676-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A077676-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A077676-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A077676-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A077676-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A077676-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A077676-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A077676-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A077676-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A077676-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A077676-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A077676-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A077676-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A077676-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A077676-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A077676-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A077676-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03A077676-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A077676-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A077676-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A077676-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09A077676-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07A077676-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A077676-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A077676-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A077676-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A077676-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A077676-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A077676-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A077676-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05A077676-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01A077676-001AB13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A077676-001AB13a93d1ddd44b…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Ciclopirox OlamineCICLOPIROX OLAMINEPadagis Israel Pharmaceuticals Ltdeadbd29d-5990-4987-833f-40cd0b2d28682026-04-16Warnings, Adverse reactionsExact identifier
ndc (product): 45802-400
Ciclopirox OlamineCICLOPIROX OLAMINEBryant Ranch Prepack399fd2d5-f5a2-4bce-ad4e-ce70060a14b02024-12-24Warnings, Adverse reactionsExact identifier
ndc (package): 72162-1406-6
ndc (package): 72162-1406-3
ndc (product): 72162-1406
ndc11 (package): 72162140606
ndc11 (package): 72162140603
spl id: bd13e41b-98e8-41f4-af32-10df498f93cc
spl set id: 399fd2d5-f5a2-4bce-ad4e-ce70060a14b0

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.